The effect of simvastatin on the mortality of sepsis patients

The effect of simvastatin on APACHE score and mortality of patients with sepsis comparing placebo: a clinical trial study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015111118543N2

Enrollment

Registered

2015-12-02

Start date

2010-04-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis. Sepsis unspecified

Interventions

Intervention 1: Placebo. Intervention 2: Administration of simvastatin (40mg/day, Osve, Iran).

Treatment - Drugs

Placebo

Administration of simvastatin (40mg/day, Osve, Iran)

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: all adult patients admitted to ICU with sepsis Exclusion criteria: Pregnancy, cirrhosis, level of AST and ALT > 3 times the upper limit of normal, CRP> 3 times the upper limit of normal, consumption of any types of statins 3 weeks before sepsis, sensitivity to statins

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
All-cause mortality. Timepoint: Immediately after treatment. Method of measurement: Questionnaire.;APACHE score. Timepoint: Days 1, 3 and 7 after sepsis. Method of measurement: The questionnaire of APACHE II system for classification of disease severity.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Reza Mirjalili

Shahid Sadoughi University of Medical Sciences

mirjalili-hmrc@ssu.ac.ir+98 35 3725 8770

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026